BR112014030534A2 - composições de galacto-ramnogalacturonato para o tratamento de doenças associadas com óxido nítrico sintase induzível elevada - Google Patents

composições de galacto-ramnogalacturonato para o tratamento de doenças associadas com óxido nítrico sintase induzível elevada

Info

Publication number
BR112014030534A2
BR112014030534A2 BR112014030534A BR112014030534A BR112014030534A2 BR 112014030534 A2 BR112014030534 A2 BR 112014030534A2 BR 112014030534 A BR112014030534 A BR 112014030534A BR 112014030534 A BR112014030534 A BR 112014030534A BR 112014030534 A2 BR112014030534 A2 BR 112014030534A2
Authority
BR
Brazil
Prior art keywords
treatment
galacto
compositions
neurodegenerative
nitric oxide
Prior art date
Application number
BR112014030534A
Other languages
English (en)
Inventor
A Klyosov Anatole
Zomer Eliezer
G Traber Peter
Original Assignee
Galectin Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galectin Therapeutics Inc filed Critical Galectin Therapeutics Inc
Publication of BR112014030534A2 publication Critical patent/BR112014030534A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/738—Cross-linked polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/736—Glucomannans or galactomannans, e.g. locust bean gum, guar gum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0029—Parenteral nutrition; Parenteral nutrition compositions as drug carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

abstract aspects of the invention provide methods for treatment of a disease associated with elevated inos including autoimmune, chronic inflammatory, neurodegenerative, or cardiovascular diseases. in particular, aspects of the invention relate to the use of a therapeutic formulation comprising a galacto-rhamnogalacturonate for the treatment of a disease associated with elevated inos including autoimmune, chronic inflammatory, neurodegenerative, or cardiovascular diseases. tradução do resumo resumo patente de invenção: “composições de galacto-ramnogalacturonato para o tratamento de doenças associadas com óxido nítrico sintase induzível elevada”. os aspectos da invenção fornecem métodos para o tratamento de uma doença associada com inos elevada incluindo doenças autoimunes, inflamatórias crônicas, neurodegenerativas, ou cardiovasculares. em particular, os aspectos da invenção referem-se ao uso de uma formulação terapêutica compreendendo um galacto-ramnogalacturonato para o tratamento de uma doença associada com inos elevada incluindo doenças autoimunes, inflamatórias crônicas, neurodegenerativas, ou cardiovasculares.
BR112014030534A 2012-06-06 2013-06-06 composições de galacto-ramnogalacturonato para o tratamento de doenças associadas com óxido nítrico sintase induzível elevada BR112014030534A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261656288P 2012-06-06 2012-06-06
PCT/US2013/044478 WO2013184892A1 (en) 2012-06-06 2013-06-06 Galacto-rhamnogalacturonate compositions for the treatment of diseases associated with elevated inducible nitric oxide synthase

Publications (1)

Publication Number Publication Date
BR112014030534A2 true BR112014030534A2 (pt) 2017-06-27

Family

ID=49712624

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014030534A BR112014030534A2 (pt) 2012-06-06 2013-06-06 composições de galacto-ramnogalacturonato para o tratamento de doenças associadas com óxido nítrico sintase induzível elevada

Country Status (13)

Country Link
US (1) US9763974B2 (pt)
EP (1) EP2858651B1 (pt)
JP (1) JP6517141B2 (pt)
KR (1) KR102071739B1 (pt)
CN (1) CN104619329B (pt)
AU (1) AU2013271585B2 (pt)
BR (1) BR112014030534A2 (pt)
CA (1) CA2875979C (pt)
ES (1) ES2848538T3 (pt)
IL (1) IL236067B (pt)
MX (1) MX2014014979A (pt)
WO (1) WO2013184892A1 (pt)
ZA (1) ZA201409195B (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008011216A2 (en) * 2006-05-16 2008-01-24 Pro-Pharmaceuticals, Inc. Galactose-pronged polysaccharides in a formulation for antifibrotic therapies
DK2797942T3 (en) 2011-12-28 2018-12-10 Galectin Therapeutics Inc Composition of Hitherto-Unknown Carbohydrate Drugs for the Treatment of Human Diseases
AU2013271585B2 (en) 2012-06-06 2018-02-01 Galectin Therapeutics, Inc. Galacto-rhamnogalacturonate compositions for the treatment of diseases associated with elevated inducible nitric oxide synthase
EP2900061B1 (en) 2012-09-17 2020-01-22 Galectin Therapeutics Inc. Method for enhancing specific immunotherapies in cancer treatment
US9339515B2 (en) 2013-02-20 2016-05-17 Galectin Therapeutics, Inc. Method for treatment of pulmonary fibrosis
CN106794211A (zh) * 2014-08-18 2017-05-31 制药创源有限公司 多聚半乳糖醛酸‑鼠李聚糖半乳糖醛酸(pgrg1)组合物
WO2020002765A1 (en) 2018-06-29 2020-01-02 Glykos Biomedical Oy Conjugates
US20210100832A1 (en) * 2019-10-02 2021-04-08 Patchor Ltd. Injectable composition for the treatment of musculoskeletal disorders and methods of use thereof
WO2021123506A1 (en) 2019-12-18 2021-06-24 Glykos Biomedical Oy Stabile conjugate

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US583A (en) 1838-01-27 Hviprovement in horizontal windmills
US7897A (en) 1851-01-14 Improvement in raising carriage-tops
US2132577A (en) 1934-08-28 1938-10-11 Gen Foods Corp Method of preparing pectin
US2444266A (en) 1944-03-31 1948-06-29 Us Agriculture Pectic materials and method of preparing same
US2503258A (en) 1948-01-23 1950-04-11 Us Agriculture Neutralization of pectinic acids with sodium bicarbonate
US4016351A (en) 1976-02-04 1977-04-05 Eschinasi Emile H Pectic substances with varying methoxyl content and process therefor
US4268533A (en) 1979-11-21 1981-05-19 General Foods Corporation Quick-set low methoxyl pectin composition
EP0181351A4 (en) 1984-05-09 1989-06-21 Univ Australian METHOD FOR MODULATING IMMUNE REACTION.
US4686106A (en) 1986-06-16 1987-08-11 General Foods Corporation Pectin food product
US5071970A (en) 1988-11-23 1991-12-10 University Of Florida Process for producing pectin with a high-to-medium methoxyl content from beet pulp
DE4011285A1 (de) 1990-04-06 1991-10-10 Steigerwald Arzneimittelwerk Arzneimittel zur behandlung von hyperlipidaemie und/oder atherosklerose
US5605938A (en) 1991-05-31 1997-02-25 Gliatech, Inc. Methods and compositions for inhibition of cell invasion and fibrosis using dextran sulfate
US7491708B1 (en) 1993-03-01 2009-02-17 David Platt Modified pectin
US5498702A (en) 1993-12-16 1996-03-12 California Natural Products Treated pectinic acid process and product
US5834442A (en) 1994-07-07 1998-11-10 Barbara Ann Karmanos Cancer Institute Method for inhibiting cancer metastasis by oral administration of soluble modified citrus pectin
US6297229B1 (en) 1994-11-14 2001-10-02 Mayo Foundation For Medical Education And Research Use of ursodeoxycholic acid to treat nonalcoholic steatohepatitis
US5760010A (en) 1995-01-01 1998-06-02 Klein; Ira Method of treating liver disorders with a macrolide antibiotic
US5681923A (en) 1995-10-06 1997-10-28 Platt; David Tumor derived carbohydrate binding protein
US6632797B2 (en) 1996-06-24 2003-10-14 Matti Siren Method of treating angiogenesis
JPH10117800A (ja) * 1996-08-30 1998-05-12 Akita Pref Gov 単糖、オリゴ糖または可溶化多糖の製造法
US7022683B1 (en) * 1998-05-13 2006-04-04 Carrington Laboratories, Inc. Pharmacological compositions comprising pectins having high molecular weights and low degrees of methoxylation
US5929051A (en) * 1998-05-13 1999-07-27 Carrington Laboratories, Inc. Aloe pectins
US6180139B1 (en) 1998-12-04 2001-01-30 Viva America Marketing, Inc. Composition and method for treating nonalcoholic steatohepatitis
US6500807B1 (en) 1999-02-02 2002-12-31 Safescience, Inc. Modified pectin and nucleic acid composition
AU4055000A (en) 1999-04-13 2000-11-14 Daniel K. Hsu Galectin expression is induced in cirrhotic liver and hepatocellular carcinoma
WO2000062774A1 (en) 1999-04-20 2000-10-26 Board Of Trustees, Southern Illinois University Methods of treating clinical diseases with isoflavones
IT1316986B1 (it) 2000-01-25 2003-05-26 Sigma Tau Ind Farmaceuti Derivati glicosamminoglicani parzialmente desolfatati nonanticoagulanti ad attivita' antiangiogenica.
CN1142272C (zh) 2000-02-02 2004-03-17 中国人民解放军军事医学科学院百环生物医学研究中心 携带人肝细胞生长因子基因的重组腺病毒的用途
IL150952A0 (en) 2000-02-04 2003-02-12 Seo Hong Yoo Preparation of aqueous clear solution dosage forms with bile acids
US6596762B2 (en) 2001-05-17 2003-07-22 The Regents Of The University Of Colorado Antioxidant compositions and use for treatment of hepatic steatosis and steatohepatitis
US6770622B2 (en) 2001-06-08 2004-08-03 Gary A. Jarvis N-terminally truncated galectin-3 for use in treating cancer
US6680306B2 (en) 2001-06-21 2004-01-20 Glycogenesys, Inc. Method for enhancing the effectiveness of cancer therapies
US20030004132A1 (en) 2001-06-22 2003-01-02 Yan Chang Method and material for treating immune diseases
HUP0401156A2 (hu) 2001-07-20 2004-12-28 Intermune, Inc. Májfibrózis kezelésére szolgáló módszerek
US6890906B2 (en) 2001-11-21 2005-05-10 Glycogenesys, Inc. Method for controlling angiogenesis in animals
US20040121981A1 (en) 2001-11-21 2004-06-24 Glycogenesys, Inc. Method for controlling angiogenesis in animals
US7312208B2 (en) 2002-08-28 2007-12-25 Asahi Kasei Pharma Corporation Quaternary ammonium compounds
JP2004107295A (ja) 2002-09-20 2004-04-08 National Agriculture & Bio-Oriented Research Organization ヒスタミン遊離抑制剤
US20040223971A1 (en) 2003-04-07 2004-11-11 Glycogenesys, Inc. Composition and uses of galectin antagonists
WO2004091634A1 (en) 2003-04-07 2004-10-28 Glycogenesys, Inc. Composition and uses of galectin antagonists
US20050008572A1 (en) 2003-04-29 2005-01-13 Ales Prokop Nanoparticular tumor targeting and therapy
US20050053664A1 (en) 2003-09-08 2005-03-10 Eliezer Zomer Co-administration of a polysaccharide with a chemotherapeutic agent for the treatment of cancer
US7078064B2 (en) 2003-12-03 2006-07-18 George Zabrecky Compositions and methods useful for treating and preventing chronic liver disease, chronic HCV infection and non-alcoholic steatohepatitis
CN102293773A (zh) 2004-02-27 2011-12-28 旭化成制药株式会社 含有苯并硫氮杂卓和苯并虑平化合物的药物
CA2582428A1 (en) 2004-03-26 2005-10-13 Glycogenesys, Inc. Modified pectins, compositions and methods related thereto
JP2008105945A (ja) 2005-02-07 2008-05-08 Ajinomoto Co Inc アディポネクチンの分泌促進又は誘導作用を有するアシルアミド化合物
EP1924294A4 (en) 2005-05-24 2010-11-03 Isis Pharmaceuticals Inc COMPOSITIONS AND USES FOR MODULATING EXPRESSION OF PTPRU
RU2007148927A (ru) 2005-05-26 2009-07-10 Метабэйзис Терапьютикс, Инк. (Us) Новые тиреомиметики, содержащие фосфиновую кислоту
ATE450526T1 (de) 2005-06-20 2009-12-15 Schering Corp Als antagonisten von histamin h3 geeignete piperidinderivate
WO2007016390A1 (en) 2005-07-28 2007-02-08 Children's Medical Center Corporation Matrix metalloproteinase inhibitors for treating fatty liver disease
US7906652B2 (en) 2005-11-28 2011-03-15 Merck Sharp & Dohme Corp. Heterocycle-substituted 3-alkyl azetidine derivatives
WO2008011216A2 (en) 2006-05-16 2008-01-24 Pro-Pharmaceuticals, Inc. Galactose-pronged polysaccharides in a formulation for antifibrotic therapies
JP5105297B2 (ja) 2006-05-25 2012-12-26 味の素株式会社 Ｐｐａｒ活性調節剤
JP2009539885A (ja) 2006-06-13 2009-11-19 メルク フロスト カナダ リミテツド ステアロイルコエンザイムａデルタ−９デサチュラーゼの阻害剤としてのアザシクロペンタン誘導体
US7999107B2 (en) 2007-01-31 2011-08-16 Merck Sharp & Dohme Corp. Substituted pyrano[2,3-B]pyridine derivatives as cannabinoid-1 receptor modulators
CA2706768C (en) 2007-11-30 2016-06-28 The Regents Of The University Of California Methods of treating non-alcoholic steatohepatitis (nash) using cysteamine products
US20110008903A1 (en) 2008-03-27 2011-01-13 Valerie Paradis Methods and kits for determining the occurrence of a liver disease in a subject
KR101074158B1 (ko) 2008-04-07 2011-10-17 재단법인 한국원자력의학원 간 보호 또는 간 질환의 예방 및 치료용 인삼다당체 조성물
WO2009151116A1 (ja) 2008-06-13 2009-12-17 持田製薬株式会社 非アルコール性脂肪肝炎の予防／改善・治療薬
JP2010229099A (ja) 2009-03-27 2010-10-14 Mochida Pharmaceut Co Ltd 脂質異常症の改善または治療薬
WO2013010134A2 (en) 2011-07-14 2013-01-17 Celula, Inc. Systems, apparatus and methods for biochemical analysis
US20130259870A1 (en) 2011-09-16 2013-10-03 Galectin Therapeutics Galactomannan polysaccharide composition for the treatment of nonalcoholic steatohepatitis and nonalcoholic fatty liver disease
DK2797942T3 (en) * 2011-12-28 2018-12-10 Galectin Therapeutics Inc Composition of Hitherto-Unknown Carbohydrate Drugs for the Treatment of Human Diseases
AU2013271585B2 (en) 2012-06-06 2018-02-01 Galectin Therapeutics, Inc. Galacto-rhamnogalacturonate compositions for the treatment of diseases associated with elevated inducible nitric oxide synthase
EP2900061B1 (en) 2012-09-17 2020-01-22 Galectin Therapeutics Inc. Method for enhancing specific immunotherapies in cancer treatment

Also Published As

Publication number Publication date
WO2013184892A1 (en) 2013-12-12
JP2015522561A (ja) 2015-08-06
CN104619329A (zh) 2015-05-13
IL236067B (en) 2020-11-30
KR20150045409A (ko) 2015-04-28
CN104619329B (zh) 2018-01-26
MX2014014979A (es) 2015-06-17
JP6517141B2 (ja) 2019-05-22
CA2875979A1 (en) 2013-12-12
ZA201409195B (en) 2015-09-30
KR102071739B1 (ko) 2020-01-30
US9763974B2 (en) 2017-09-19
CA2875979C (en) 2021-01-26
EP2858651A4 (en) 2016-02-17
US20150147338A1 (en) 2015-05-28
AU2013271585A1 (en) 2015-01-22
AU2013271585B2 (en) 2018-02-01
EP2858651B1 (en) 2020-11-11
IL236067A0 (en) 2015-01-29
ES2848538T3 (es) 2021-08-10
EP2858651A1 (en) 2015-04-15

Similar Documents

Publication Publication Date Title
BR112014030534A2 (pt) composições de galacto-ramnogalacturonato para o tratamento de doenças associadas com óxido nítrico sintase induzível elevada
CY1124307T1 (el) Φαρμακευτικη συνθεση, μεθοδοι θεραπειας και χρησεις αυτων
BR112015027282A8 (pt) formulação líquida e kit compreendendo fenfluramina, e usos da mesma no tratamento de síndrome de dravet
BR112017018368A2 (pt) composições contendo rna para o tratamento de doenças tumorais
EA201491819A1 (ru) Фармацевтические композиции для комбинированного лечения
BR112017009497A2 (pt) polinucleotídeos de aadc para o tratamento da doença de parkinson
MX2018002631A (es) Inhibidores de molecula pequeña de dyrkia y usos de los mismos.
BR112017007072A2 (pt) compostos de triazolopiridina e métodos para o tratamento de fibrose cística
GB201209613D0 (en) New compounds
EA201501032A1 (ru) Фармацевтическая композиция, способы лечения и ее применения
EA201490748A1 (ru) Лечение рассеянного склероза комбинацией лахинимода и финголимода
MX2015006234A (es) Uso de akkermansia para tratar trastornos metabolicos.
BR112015007985A8 (pt) uso do carboidrato galactose denteada para preparação de composições para tratamento de nefropatia diabética e de distúrbios associados, e suas composições
BR112015022197A8 (pt) uso de um composto para fabricação de um medicamento ou composição farmacêutica para o tratamento de cataplexia
MX366899B (es) Nuevos compuestos.
BR112015029386A8 (pt) uso de eribulina e lenvatinibe como terapia de combinação, composição farmacêutica compreendendo os mesmos e kit
BR112015015870A8 (pt) composição farmacêutica, e, uso de uma composição farmacêutica
MX2016005446A (es) Intervenciones a base de angiopoyetina para tratar la malaria cerebral.
CL2013000455A1 (es) Compuestos derivados oxadiazol, inhibidores de la produccion de leucotrienos; composicion farmaceutica que lo comprende; y su uso en el tratamiento de enfermedades cardiovasculares, inflamatorias, alergicas, pulmonares y fibroticas y cancer.
BR112014016389A8 (pt) composições e uso das mesmas para o tratamento de distúrbios e doenças hepáticas
WO2014151456A3 (en) Treatment of inflammatory diseases
WO2014107730A3 (en) Use of fatty acid niacin conjugates for treating diseases
EA201391440A1 (ru) Производные пиразолопиримидина
EA201690191A1 (ru) Фармацевтическая композиция для замедленного высвобождения ланреотида
EA201491532A1 (ru) Фармацевтические композиции для использования в комплексной терапии

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06I Publication of requirement cancelled [chapter 6.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 6.6.1 NA RPI NO 2462 DE 13/03/2018 POR TER SIDO INDEVIDA.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B11E Dismissal acc. art. 34 of ipl - requirements for examination incomplete
B11T Dismissal of application maintained [chapter 11.20 patent gazette]